Cargando…

Early Changes in [(18)F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts

We investigated the potential use of [(18)F]FDG PET as a response biomarker for PI3K pathway targeting therapies in two HER-2-overexpressing cancer models. Methods. CD-1 nude mice were inoculated with HER-2-overexpressing JIMT1 (trastuzumab-resistant) or SKOV3 (trastuzumab-sensitive) human cancer ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dockx, Yanina, Vangestel, Christel, Van den Wyngaert, Tim, Huizing, Manon, De Bruycker, Sven, Pauwels, Patrick, Staelens, Steven, Stroobants, Sigrid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169268/ https://www.ncbi.nlm.nih.gov/pubmed/34113218 http://dx.doi.org/10.1155/2021/5594514

Ejemplares similares

How to Modulate Tumor Hypoxia for Preclinical In Vivo Imaging Research
por: De Bruycker, Sven, et al.
Publicado: (2018)

Effects of metformin on tumor hypoxia and radiotherapy efficacy: a [(18)F]HX4 PET imaging study in colorectal cancer xenografts
por: De Bruycker, Sven, et al.
Publicado: (2019)

Characterization of [(99m)Tc]Duramycin as a SPECT Imaging Agent for Early Assessment of Tumor Apoptosis
por: Elvas, Filipe, et al.
Publicado: (2015)

Longitudinal Characterization of [(18)F]-FDG and [(18)F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model
por: Waldron, Ann-Marie, et al.
Publicado: (2016)

Preclinical Evaluation of a Novel (18)F-Labeled dTCO-Amide Derivative for Bioorthogonal Pretargeted Positron Emission Tomography Imaging
por: Ruivo, Eduardo, et al.
Publicado: (2020)

ATG4B Inhibitor UAMC-2526 Potentiates the Chemotherapeutic Effect of Gemcitabine in a Panc02 Mouse Model of Pancreatic Ductal Adenocarcinoma
por: Takhsha, Farnaz Sedigheh, et al.
Publicado: (2021)

The Effects of Physiological and Methodological Determinants on (18)F-FDG Mouse Brain Imaging Exemplified in a Double Transgenic Alzheimer Model
por: Deleye, Steven, et al.
Publicado: (2016)

First-in-human study of a novel cell death tracer [(99m)Tc]Tc-Duramycin: safety, biodistribution and radiation dosimetry in healthy volunteers
por: Metelerkamp Cappenberg, Taco, et al.
Publicado: (2023)

Awake (18)F-FDG PET Imaging of Memantine-Induced Brain Activation and Test–Retest in Freely Running Mice
por: Miranda, Alan, et al.
Publicado: (2019)

Characterization of Structurally Diverse (18)F-Labeled d-TCO Derivatives as a PET Probe for Bioorthogonal Pretargeted Imaging
por: Adhikari, Karuna, et al.
Publicado: (2023)

Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
por: Vandamme, Timon, et al.
Publicado: (2016)

(18)F-FDG-PET/CT for the detection of disease in patients with head and neck cancer treated with radiotherapy
por: Helsen, Nils, et al.
Publicado: (2017)

Neuroreceptor kinetics in rats repeatedly exposed to quinpirole as a model for OCD
por: Servaes, Stijn, et al.
Publicado: (2019)

Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders—An Update
por: Dewulf, Jonatan, et al.
Publicado: (2020)

Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
por: Holloway, Ryan W., et al.
Publicado: (2021)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

Acute Ketamine Infusion in Rat Does Not Affect In Vivo [(11)C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5
por: Kosten, Lauren, et al.
Publicado: (2018)

Translation of Preclinical PET Imaging Findings: Challenges and Motion Correction to Overcome the Confounding Effect of Anesthetics
por: Miranda, Alan, et al.
Publicado: (2021)

Spatiotemporal Kernel Reconstruction for Linear Parametric Neurotransmitter PET Kinetic Modeling in Motion Correction Brain PET of Awake Rats
por: Miranda, Alan, et al.
Publicado: (2022)

Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
por: Schayowitz, A, et al.
Publicado: (2010)

A simulation study on the impact of the blood flow-dependent component in [(18)F]AV45 SUVR in Alzheimer’s disease
por: Ottoy, Julie, et al.
Publicado: (2017)

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
por: Cao, Guo-dong, et al.
Publicado: (2017)

Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [(11)C]UCB-J PET study in a model of obsessive–compulsive disorder-like behaviour
por: Glorie, Dorien, et al.
Publicado: (2020)

Usefulness of Splenic Scintigraphy in Differentiating Splenosis and Malignancy on Gallium 68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-NaI3-octreotide
por: Van Hecke, Stijn, et al.
Publicado: (2018)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Immunohistochemical Investigation of HER/AKT/mTOR Pathway and Cellular Adhesion Molecules in Urothelial Carcinomas
por: Koletsas, Nikolaos, et al.
Publicado: (2017)

Chronic modulation of AMP-Kinase, Akt and mTOR pathways by ionizing radiation in human lung cancer xenografts
por: Storozhuk, Yaryna, et al.
Publicado: (2012)

Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth
por: Kannan, Aarthi, et al.
Publicado: (2015)

Estimation of and correction for finite motion sampling errors in small animal PET rigid motion correction
por: Miranda, A., et al.
Publicado: (2018)

Molecular Imaging of Apoptosis: The Case of Caspase-3 Radiotracers
por: Beroske, Lucas, et al.
Publicado: (2021)

Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators
por: Moon, Euy Sung, et al.
Publicado: (2020)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor
por: Sun, Lu, et al.
Publicado: (2015)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

MicroPET Outperforms Beta-Microprobes in Determining Neuroreceptor Availability under Pharmacological Restriction for Cold Mass Occupancy
por: Glorie, Dorien, et al.
Publicado: (2017)

mTOR and lysosome regulation
por: Puertollano, Rosa
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r5clu7hm1ldi9ck9t17pjvj880